Aeglea BioTherapeutics, Inc./$SYRE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Aeglea BioTherapeutics, Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Ticker

$SYRE
Primary listing

Industry

Biotechnology

Employees

73

ISIN

US00773J2024

SYRE Metrics

BasicAdvanced
$910M
-
-$3.01
2.80
-

Bulls say / Bears say

Aeglea BioTherapeutics' acquisition of Spyre Therapeutics in June 2023 has significantly bolstered its pipeline with promising antibody therapeutics targeting inflammatory bowel disease (IBD), positioning the company to capture a substantial share of the growing IBD market. (proactiveinvestors.com)
The sale of global rights to pegzilarginase to Immedica Pharma AB in July 2023 provided Aeglea with $15 million upfront and potential milestone payments up to $100 million, enhancing its financial position to support ongoing and future projects. (marketscreener.com)
Analyst coverage initiated by Stifel in July 2023 with a 'Buy' recommendation and a significant price target increase reflects growing confidence in Aeglea's strategic direction and potential for substantial stock appreciation. (nasdaq.com)
The interim analysis of the Phase I/II study for pegtarviliase in April 2023 failed to meet its objectives, leading to a 26% stock decline and raising concerns about the efficacy of Aeglea's pipeline. (nasdaq.com)
Aeglea's decision to lay off a significant portion of its workforce in April 2023, retaining only about 10 employees, indicates financial strain and potential challenges in sustaining operations. (fiercebiotech.com)
The company's shift in focus to IBD treatments following the acquisition of Spyre Therapeutics introduces execution risks associated with entering a competitive market and developing new therapies. (proactiveinvestors.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SYRE

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs